Table 1.

Clinical characteristics of 67 patients with uterine serous carcinoma.

Characteristic	Number
Age (mean, standard deviation, in years), range	65.8 +/- 8.3, 44-82
Race
Black White Asian More than one	33 (49.2%) 32 (47.8%) 1 (1.5%) 1 (1.5%)
Ethnicity
Hispanic Non-Hispanic	15 (22.4%) 52 (77.6%)
Treatment
Surgery	52 (78%)
TAH “ + BSO “ + BSO + PLND “ + BSO + PLND + Omentectomy and debulking	2 2 10 38
Initial chemotherapy	65 (97%)
Carboplatin “ + Paclitaxel “ + Paclitaxel + Bevacizumab “ + Paclitaxel + Herceptin “ + Paclitaxel + Pembrolizumab “ + Taxotere “ + Taxotere + Bevacizumab	2 55 4 1 1 1 1
Radiation therapy	23 (34.3%)
FIGO Stage at diagnosis
I II III IV	13 (19.4%) 3 (4.5%) 18 (26.9%) 33 (49.2%)
Metastatic disease	33 (49.2%)
Recurrent disease	27 (40.3%)
Mutational status
TP53 PIK3CA FBXW7 ARID1A PTEN BRCA1 BRCA2 CTNNB1 ERBB2 alterations AKT1,2,3 KRAS	55/58 (94.8%) 14/61 (22.9%) 10/60 (15%) 3/32 (9.4%) 5/57 (8.7%) 2/57 (3.5%) 2/57 (3.5%) 1/58 (1.7%) 12/37 (32.4%) 2/61 (3.3%) 1/61 (1.6%)
Immunohistochemistry
ER PR PTEN TOP2A TOP01 RRM1 MGMT TS TUBB3	43/65 (66.2%) 24/65 (36.9%) 51/56 (91.1%) 20/22 (90.9%) 14/22 (63.6%) 4/20 (20%) 3/5 (60%) 10/22 (45.5%) 11/22 (50%)

TAH, total hysterectomy; BSO, Bilateral salpingoophorectomy; PLND, pelvic lymph node dissection.